Anti–PD-1 therapy (pembrolizumab, nivolumab) supports neoadjuvant and adjuvant management of higher-risk melanoma, offering durable remissions with less systemic toxicity than traditional chemotherapy ...
Skin malignancies are the most common cancers in the United States. 1 Typically, skin cancer is categorized as either melanoma or nonmelanoma skin cancer, which is also known as keratinocyte ...
Libtayo's FDA approval offers an effective adjuvant option for high-risk cutaneous squamous cell carcinoma, reducing recurrence risk by 68% in the C-POST trial. Administered post-surgery and radiation ...
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas ASCO Guidelines ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Samuel J. Klempner ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results